drug
epoetin zeta
Marketedupdated 6mo agoby Vifor Pharma Inc
Approvedcommunity read0 votes
all catalysts(0)
nothing on the calendar yet
News(1)
- CSL pays $355M to co-develop Alentis’ phase 2-stage fibrosis drugAustralia’s CSL is paying $355 million upfront for the rights to Alentis Therapeutics’ phase 2-stage fibrosis drug.fiercebiotech · 27d ago
Data sources
last refreshed 35m ago
Found something off?
comments(0)
5-min edit window · permanent after that